期刊
NANOMEDICINE
卷 17, 期 18, 页码 1281-1303出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2022-0092
关键词
green synthesis optimization; in vitro activity and toxicity; physiologically based pharmacokinetics; toxicokinetic; ZnO nanoparticles
Research on ZnO nanoparticles has various medical applications, but optimizing the green synthesis of these nanoparticles is complex. ZnO nanoparticles exhibit toxicity at lower doses, which is influenced by their properties, pharmacokinetics, and the species type and age of the tested animals. Physiologically based pharmacokinetic modeling can be used to understand the collaborative effects of these factors, reducing the need for in vivo studies. This review serves as a guide for choosing green synthesis conditions that minimize toxicity using pharmacokinetic modeling.
Research on ZnO nanoparticles (NPs) has broad medical applications. However, the green synthesis of ZnO NPs involves a wide range of properties requiring optimization. ZnO NPs show toxicity at lower doses. This toxicity is a function of NP properties and pharmacokinetics. Moreover, NP toxicity and pharmacokinetics are affected by the species type and age of the animals tested. Physiologically based pharmacokinetic (PBPK) modeling offers a mechanistic platform to scrutinize the colligative effect of the interplay between these factors, which reduces the need for in vivo studies. This review provides a guide to choosing green synthesis conditions that result in minimal toxicity using a mechanistic tool, namely PBPK modeling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据